Isobavachalcone sensitizes cells to E2-induced paclitaxel resistance by down-regulating CD44 expression in ER+ breast cancer cells

Junfeng Shi, Yi Chen, Wenxing Chen, Cuiju Tang, Honghong Zhang, Yuetong Chen, Xiuwei Yang, Zhi Xu, Jingsun Wei, Jinfei Chen

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Oestrogen receptor (ER) is expressed in approximately 60%-70% of human breast cancer. Clinical trials and retrospective analyses have shown that ER-positive (ER+) tumours are more tolerant to chemotherapeutic drug resistance than ER-negative (ER−) tumours. In addition, isobavachalcone (IBC) is known as a kind of phytoestrogen with antitumour effect. However, the underlying mechanism of IBC in ER+ breast cancer needs to be elucidated further. Our in vitro experiments showed that IBC could attenuate 17β-estradiol (E2)-induced paclitaxel resistance and that E2 could stimulate CD44 expression in ER+ breast cancer cells but not in ER− cells. Meanwhile, E2 could promote ERα expression to render ER+ breast cancer cells resistant to paclitaxel. Furthermore, we established paclitaxel-resistant breast cancer cell lines and determined the function of ERα in the enhancement of paclitaxel resistance via the regulation of CD44 transcription. IBC down-regulated ERα and CD44 expression and thus inhibited tumour growth in paclitaxel-resistant xenograft models. Overall, our data demonstrated for the first time that IBC could decrease CD44 expression level via the ERα pathway and make ER+ breast cancer cells sensitive to paclitaxel treatment.

Original languageEnglish
Pages (from-to)5220-5230
Number of pages11
JournalJournal of Cellular and Molecular Medicine
Volume22
Issue number11
DOIs
StatePublished - Nov 2018

Bibliographical note

Funding Information:
the project of Science & Technology of Nanjing, Grant/Award Number: YKK14081; the Natural Science Foundation of Jiangsu Province, Grant/Award Number: BK20150092; the National Natural Science Foundation of China, Grant/Award Number: 81502623; the Key R & D Special Fund of Jiangsu Province, Grant/Award Number: BE2017611

Publisher Copyright:
© 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

Keywords

  • CD44
  • breast cancer
  • isobavachalcone
  • oestrogen receptor alpha
  • paclitaxel resistance

ASJC Scopus subject areas

  • Molecular Medicine
  • Cell Biology

Fingerprint

Dive into the research topics of 'Isobavachalcone sensitizes cells to E2-induced paclitaxel resistance by down-regulating CD44 expression in ER+ breast cancer cells'. Together they form a unique fingerprint.

Cite this